You are here: Industry Insights > NICE

News List

NICE backs Lilly’s Taltz for axial spondyloarthritis pharmatimes
June 18, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Taltz for the treatment of active ankylosing spondylitis (axSpA).
New NICE guidance supports shared decision making pharmatimes
June 18, 2021
New recommendations published by the National Institute for Health and Care Excellence (NICE) advise that shared decision making should become routine across all healthcare settings.
NICE to reassess Kyowa Kirin’s Poteligeo pharmatimes
June 16, 2021
The National Institute for Health and Care Excellence (NICE) will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by the companies and various charities.
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients pharmatimes
June 16, 2021
Bristol Myers Squibb’s (BMS) immunotherapy combination Opdivo plus Yervoy has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of certain advanced bowel cancer patients.
NICE broadens access to treatments for rheumatoid arthritis pharmatimes
June 16, 2021
The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis.
Astellas’ Xtandi bags NICE approval in prostate cancer pharmatimes
June 10, 2021
Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
NICE recommends Tecentriq for first-line NSCLC pharmatimes
June 09, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC).
NICE draft guidance does not recommend Evrysdi for SMA pharmatimes
June 04, 2021
The UK National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Roche’s Evrysdi for the treatment of spinal muscular atrophy (SMA) in draft guidance.
NICE turns down GSK's IV Benlysta for systemic lupus pharmatimes
June 04, 2021
The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page